Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial

INTRODUCTION: In a first-in-human study immune responses to rabies virus glycoprotein (RABV-G)-mRNA vaccine were dependent on the route of administration, necessitating specialized devices. Following successful preclinical studies with mRNA encapsulated in lipid nanoparticles (LNP), we tested an mRN...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldrich, Cassandra, Leroux–Roels, Isabel, Huang, Katell Bidet, Bica, Mihai Alexandru, Loeliger, Edde, Schoenborn-Kellenberger, Oliver, Walz, Lisa, Leroux-Roels, Geert, von Sonnenburg, Frank, Oostvogels, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825876/
https://www.ncbi.nlm.nih.gov/pubmed/33487468
http://dx.doi.org/10.1016/j.vaccine.2020.12.070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825876/
https://www.ncbi.nlm.nih.gov/pubmed/33487468
http://dx.doi.org/10.1016/j.vaccine.2020.12.070

Ejemplares similares